Every fact traced to its source, and checked against it. We track the entities shaping AI — verify a claim, or open a knowledge file.
Conclusions our AI is drawing from the traced facts — read them as interpretation, each grounded in the data and the entities it names.
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
In October-November 2026, vendors across the stack turned AI into operational products. Fortinet, Cisco and T-Mobile focused on securing AI and the network, Encord and Harvest Praxis/MediaTek on physical-AI data and chips, and NVIDIA RTX Spark laptops and the new iPad mini on edge hardware. Salesforce's Braze acquisition shows consolidation toward AI-driven customer engagement, while small-cap TEN Holdings restructures toward SaaS. Executives are broadly upbeat but frame the bottleneck as data, security and integration cost rather than model capability.
The 2026 ESMO Congress drove a cluster of late-October oncology data releases and launches: Summit's ivonescimab, Incyte's pancreatic cancer (PDAC) pipeline, Astellas' CLDN18.2 real-world evidence, AstraZeneca's ZEGFROVY US launch and Abbott's whole-genome sequencing (WGS) MRD test. At the same time, smaller or struggling players are retrenching through a Nasdaq First North delisting, a SPAC LOI, and ADC Therapeutics' workforce cuts to extend its cash runway into 2028. The picture is a strong clinical and commercial pipeline for well-capitalized leaders and cost-cutting or exits for the rest, with little visible financing optimism for the small end of the market.
A sharp mid-October to early-November 2026 semiconductor and AI/data-center selloff (SOX's longest losing streak since 2008, its worst session since March 2020, and the S&P 500's worst day since April 2025) pushed the VIX higher. It hit amid midterm-election uncertainty, mixed earnings guidance (Trimble's 2027 headwind) and growing concern over unprecedented AI capex and legal and regulatory pressure. Underneath, AI adoption keeps broadening into healthcare, defense, education and enterprise software, the Anthropic IPO is expected to be a market bellwether, and bull-case valuations (Alphabet's $427.89 fair value) rest on converting AI engagement into earnings. Fraud cases like Joonko, where the founder pleaded guilty to securities fraud, add a note of investor-protection caution.
On Nov 5, 2026 the Nasdaq had its worst day since April 2025. The Magnificent Seven lost over $1 trillion, and Tesla and SpaceX lost over $420 billion combined. The next day Democrats signaled plans to rein in Big Tech, and Tesla said it would wind down Cybertruck production. Over the same period, financial-services firms such as East West Bancorp, FNF, LY Corp (PayPay/fintech) and Canara HSBC Life reported solid earnings, raised guidance and increased dividends. JPMorgan's selective aerospace and defense ratings point to investors rotating toward earnings-backed names, while AI-investor enthusiasm (IEQ Capital's party, Viola FinTech's 40 NYC AI portfolio companies) and enterprise AI adoption (Lenovo edge computer vision at a European retail bank) continue.
The Q3 2026 reporting window is dominated by large capital events: OpenAI's round closing at about $1.25T, Fox's DOJ-cleared Roku deal, and Shield AI's purchase of Echodyne. Executives in credit (Robert Stanley's BDC commentary on stable spreads, a favorable rate path, and M&A expected to pick up in Q1–Q2 2027 after the election), fintech and prediction markets (DraftKings' customer-acquisition spend), and small-cap SaaS (TEN Holdings' cost cuts and 17.9% revenue growth) describe a selectively healthy environment. Scheduled CEO transitions (Davis, Hogan) and year-end regulatory and rate changes (Alberta auto reform, Florida City Gas) add continuity and policy risk. Biotech data readouts such as Arrowhead's are present but peripheral to the AI-finance theme.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Samsung will likely announce a unified smart home AI platform or hub within 2-3 months that connects these disparate AI-enabled products
Sustained AI feature expansion across Samsung ecosystem in Q1-Q2 2026, with likely follow-up announcements for mobile devices and additional appliances
NVIDIA GPU acceleration is becoming the dominant infrastructure for AI chip design and EDA workflows, creating a self-reinforcing ecosystem where AI chips are designed using AI-accelerated tools
88% confidence · untestedData center infrastructure investments are shifting from traditional cloud providers to AI-specific facilities, with hyperscalers willing to commit $20B+ multi-year contracts for AI-optimized data center capacity, creating opportunities for specialized infrastructure developers
88% confidence · untestedLLM sycophancy is primarily caused by reinforcement learning from human feedback (RLHF) optimization for user approval rather than truthfulness, creating a systematic bias that degrades model reliability in extended conversations
85% confidence · untestedAI safety concerns are escalating as models gain access to classified and sensitive data, creating new security vulnerabilities and ethical challenges around training data governance
85% confidence · untestedHyperscaler AI infrastructure investments exceeding $200B combined will drive semiconductor demand and AI chip production capacity expansion in 2026
85% confidence · untestedArgan outlines $2.9B backlog strength and signals continued demand for large power projects
“Argan outlines $2.9B backlog strength and signals continued demand for large power projects Earnings Call Insights: Argan, Inc…”
QCI CTO Andrew Cardno to Take the Stage for Key Sessions on Security Innovation and Player Engagement at IGA 2026
“QCI CTO Andrew Cardno to Take the Stage for Key Sessions on Security Innovation and Player Engagement at IGA 2026 SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Quick Custom Intelligence (QCI) Co-Founder and Chief Technology Officer Andrew Cardno will take the stage at the Indian Gaming Association Tradeshow & Conventio…”
Trump sues ‘woke’ JP Morgan for $5bn over debanking
“Trump sues ‘woke’ JP Morgan for $5bn over debanking Donald Trump is suing JP Morgan and its chief executive, Jamie Dimon. - Krisztian Bocsi/Bloomberg Donald Trump is suing JP Morgan and its chief executive Jamie Dimon for $5bn (£3.7bn) over claims it debanked him…”
Can quantum computers now solve health care problems? We’ll soon find out.
“MIT Technology Review - Ai Research Title: Can quantum computers now solve health care problems? We’ll soon find out…”
Stocks Surge on Signs the US and Iran Seek to End War
“Stocks Surge on Signs the US and Iran Seek to End War The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +2.49%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.43%…”
We All Know We Should Have An Emergency Fund. But One Homeowner Cautions Not To Name It 'House Emergency Fund.' Here's Why
“We All Know We Should Have An Emergency Fund. But One Homeowner Cautions Not To Name It 'House Emergency Fund.' Here's Why Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…”
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Two different margin values (16% vs 18%) are recorded for the same entity (Shopify Inc.) at the identical timestamp (2026-08-05 00:00:00). With no distinguishing context (same period designation, no qualifier for margin type), these represent conflicting data about the same fact.
Fact B (Q1 2026) and Fact A (Q2 2026) are recorded as observed on the same date: 2026-03-29. This is temporally impossible, since Q2 2026 (April–June) has not yet occurred as of 2026-03-29 (mid-Q1). Financial results for a future period cannot be observed before that period ends. Additionally, 3.7 USD is implausibly low as a cash position for Qualcomm Incorporated, suggesting a data entry error in Fact B.
Both facts measure EPS for Citigroup with identical observation dates (2025-12-31). FACT A explicitly specifies FY 2025 annual EPS at 6.99 USD/share, while FACT B reports 1.65 USD with an unspecified fiscal period (N/A). The values differ by a factor of ~4.2x, which is too large to explain by rounding, methodology, or data quality variance. While FACT B's 'N/A' fiscal period introduces ambiguity about whether it represents the same annual period, both observations are timestamped identically and purport to measure the same metric on the same date. If both represent FY 2025 annual EPS, this is a direct value conflict. If FACT B represents a different period (e.g., quarterly, TTM, or interim), the ambiguous labeling still constitutes a data quality issue that obscures the reconciliation.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Every fact is traceable to the document it came from — see how we source every claim.
The checked evidence shows two AI-in-finance developments: a startup raising $35M to verify AI agents' identities, and a Japanese internet group raising guidance on AI-driven gains. Robinhood's SEC-verified financials supply the market-side context. Source reliability is mixed, and we flag where.
Nasdaq plans a 23-hour trading day, Cboe and Robinhood plan company-specific KPI contracts, and startups are building identity checks for AI agents. We trace each claim to its source and flag where the evidence is thin or the sources disagree.
Micron's capital spending roughly doubled in a year, and Nvidia is co-developing memory to secure supply. Via News checked the figures against SEC filings and graded the sources. The sources behind several headline claims are weaker than the SEC-backed numbers.
Fintech money is moving toward identity and payments for AI agents, led by Baselayer's $35M Series A. One investor warns that AI should not do the maths. Via News checked the claims: Robinhood's SEC-filed figures anchor the picture, and the thin evidence is flagged.
As trading moves toward 23-hour days and retail event contracts, a startup is raising $35M to verify the AI agents that may transact in them, while a Norwest investor says AI shouldn't do finance maths. Figures here come from fidelity-checked SEC data and named, dated sources.
Radical Numerics says AI-designed viruses have treated its first patient, the clearest AI-therapeutics milestone in a crowded late-2026 biotech news cycle. The claim is unverified, so we set it against audited Incyte figures and checked trial and royalty data.
In Q3 2026 earnings calls, Lam Research's CFO guided to $8.6B of December-quarter revenue and said supply chains were the limit on AI-driven chip demand. Dow and Union Pacific talked cost cuts and fuel. We checked Dow's SEC-filed numbers against what its CFO said.
Lam Research's CFO said the AI-driven chip-equipment boom is held back by supply chains, not demand. Dow and Union Pacific are cutting costs against high energy and fuel prices. This piece is built from Q3 2026 earnings-call transcripts and SEC-filed Dow figures.
Dow, Union Pacific and Rio Tinto are hitting profit targets with job cuts, fuel pass-throughs and volume, not AI. The agentic-AI case in this dossier is a vendor press release with no customer results. We cite SEC-checked Dow figures and the speakers' own words.
Dow and Union Pacific are meeting an energy-cost shock with internal cost programs and cash discipline, not growth bets. For AI watchers the dossier's verified evidence is thin: agentic AI shows up in vendor claims, not in these CFOs' results. Dow's SEC-checked history supplies the baseline.
Robinhood announced an 'agent' product and Cboe KPI contracts in the same week Baselayer raised $35M to verify AI agents. Robinhood's SEC-verified revenue has risen from $1.87B to $4.47B in two years. The dossier says nothing about what Robinhood Agent does, so this piece separates what is checked from what is not.
In the week of 15 to 20 October 2026, ServiceNow launched a signed credential for AI agents and Salesforce agreed to buy Braze. Both moves treat enforced control as the product. Figures here come from SEC-checked data and company releases, with source reliability noted.
Oncology reaches ESMO with regulatory wins and heavy antibody-drug conjugate (ADC) interest. For AI readers, the more telling story is the 'lab of the future' pitch, which is only stated intent, from a source whose claims did not check out. Summit's audited filings show what drug development costs.
Analysts upgraded Palantir on customer expansion and the finding that customer-built AI apps complement its platform. Partnerships ran from banking to sovereign AI. The stock still fell five sessions in a row, and J.P. Morgan was cautious on defense. Every claim here is tied to a named source.
AstraZeneca's Puja Sapra describes agentic, de novo biologics design and automated 'labs of the future'. The source documents no demonstrated result, and our checks found none of its 11 claims held up. Meanwhile, SEC-verified filings show what a late-stage oncology bet costs: Summit's FY2025 net loss was about five times FY2024's.
Analysts upgraded Palantir on a thesis that customer-built AI apps complement its platform. Partnerships in banking and sovereign AI followed, then a 7% one-day drop. J.P. Morgan is cautious on traditional defense names. Every claim below is traced to a named source, with reliability noted.
An AstraZeneca executive describes AI-driven, increasingly automated biologics design as oncology's longer-term engine. The source checks out at 0% of 11 claims. The hard evidence is elsewhere: Summit's SEC-verified filings show how costly the bispecific bet is before a Nov 14 FDA decision.
In the week to 14 October 2026, Cisco, Hesai, Zeta and TELUS Digital/Parloa each announced a different layer of the AI stack. Nvidia's SEC-checked filings show cost of revenue up more than 3.7x in two fiscal years. Most announcements are company press releases, a weaker source class, and we flag where.
SAP, Zeta and others announced agent platforms within days of each other in October 2026. The smaller deals show where the field is spending: Tiny bought the authorization company Oso Cloud for about $1.9 million in cash. EDB says policy must be enforced by the system, and a Norwest investor says AI shouldn't do finance calculations. Sources are cited, and two carry measured reliability scores.
AstraZeneca's Puja Sapra describes AI that designs molecules and robots that test them, just as oncology enters a dense run of regulatory and trial events. The AI claims come from one source whose checked claims did not hold up, so we separate what is verified from what is promised.
Micron's capital spending more than doubled in a year, to $15.9 billion in fiscal 2025, according to SEC-sourced figures. Nvidia, Bull and Kalray, and GlobalFoundries are all moving on memory supply and data movement. The sources behind these deals vary a lot in reliability, and we show that.
AstraZeneca's scientist argues that proprietary data, robots and AI will design the next biologics, but the article carrying her case scored 0% on our claim check. The only AI-adjacent oncology company with audited numbers here is Summit, whose FY2025 loss was $1.08 billion.
Nvidia is co-developing next-generation SK Hynix memory to secure HBM supply, while SEC filings show Micron's annual capex more than doubled in two years. Verified filings, plus some thinner, lower-reliability sources, show where the AI hardware squeeze is hitting.
Q4 2026 brings an FDA decision date for ivonescimab and the first detailed data for Merck and Moderna's personalised cancer vaccine. AstraZeneca is pitching AI-designed biologics to shorten discovery. We separate SEC-verified Merck figures from vendor-voice claims, and flag the AI source's weak fact-check record.
AstraZeneca describes AI that proposes, robots that test and humans who oversee, while mRNA vaccines and ADC-bispecific combinations head for key dates. Our dossier checks the AI claims against reliability data and Merck's filings. The AI claims rest on a source whose checked claims did not hold up.
SEC-filed figures show Micron's capital spending nearly doubled in fiscal 2025 and its cash reached about $25 billion by Q3 2026. Analyst enthusiasm for AI power and compute names runs well ahead of the evidence in places: D-Wave trades at 171x sales, and one source behind the NuScale call scores 22% on reliability.
Every fact here is structured and source-traced — so AI systems inherit ground truth, not re-narrated claims. The same facts a person reads, a model can query.